back to Directory

BenevolentAI

BenevolentAI logo

Founded
2013
Patents
38
Clinical Trials
1
Publications
47

Technologies

AI Companies (Drug Discovery) Pharmaceutical and Drug Discovery

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discoverytowards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.


Posts Mentioning This Company

13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)

  
According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies.  Some companies are incorporating AI tools …

11 Biopharma Trends to Watch in 2024

  
2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

Tech-First Companies Take the Lead in AI Drug Discovery

  
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery. These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial intelligence, enhancing its technology-enabled drug discovery capabilities …

How Big Pharma Adopts AI To Boost Drug Discovery

  
(Last updated: July 2023) The type of artificial intelligence (AI) which scares business leaders, experts, and activists all over the world, is called “general artificial intelligence"—the  one which could “think” pretty much like humans do, and which could quickly evolve into a dangerous “superintelligence”. There is a notion that it …

BenevolentAI Pioneers AI-Driven Drug Discovery for ALS Treatment

  
Incorporating AI in drug discovery is rapidly becoming a common practice in the pharmaceutical industry. The recent undertakings of UK-based biotech company BenevolentAI, which is listed on Euronext Amsterdam (BAI), further validate this trend. The company utilises advanced AI technologies to streamline biopharmaceutical discovery, a fact well illustrated by the …

2022 in Retrospect: 10 Breakthrough Technologies in Drug Discovery

  
Reflecting on 2022, let’s review several breakthrough technologies that are shaping the future of biology research and drug discovery. I have prepared this list based on a review of recent articles published on BiopharmaTrend -- by myself and by numerous guest authors.

Insilico Medicine and Other AI Drug Discovery Companies Leading the Race

  
A Hong Kong-based artificial intelligence (AI)-driven drug discovery company Insilico Medicine has just announced the appointment of Dr. Michelle Chen as a Chief Business Officer (CBO) to oversee the company’s corporate strategies and business development activities. Dr. Chen is a lofty hire, having more than 20 years of experience in …

Pharma and Healthcare AI Vendors Join Forces To Accelerate Progress In Drug Discovery

  
Today Basel is crowded with some of the top business and research leaders representing a young and rapidly growing industry of artificial intelligence (AI) in healthcare and pharmaceutical research. They come together to announce mission and launch activities of a global Alliance for Artificial Intelligence in Healthcare (AAIH), which is …

How AI Helps Validate Life Science Hypotheses

  
In this interview, Dr. Jackie Hunter, CEO at BenevolentAI, provides insights into how the company’s AI-driven platform helps scientists create and validate complex research hypotheses faster and more efficiently.